Fund, L.P. Longwood Net Worth

What's Fund Longwood's mailing address?

Fund's mailing address filed with the SEC is C/O VERASTEM, INC., 215 FIRST STREET, SUITE 440, CAMBRIDGE, MA, 02142.

Insiders trading at Verastem Inc

Over the last 13 years, insiders at Verastem Inc have traded over $5,883,823 worth of Verastem Inc stock and bought 3,873,819 units worth $28,318,633 . The most active insiders traders include Capital Management, L.P.Ra ..., Christoph H Westphal und Ansbert Gadicke. On average, Verastem Inc executives and independent directors trade stock every 28 days with the average trade being worth of $112,479. The most recent stock trade was executed by Dan Paterson on 5 August 2024, trading 3,245 units of VSTM stock currently worth $7,009.

What does Verastem Inc do?

verastem, inc. (nasdaq: vstm) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. cancer stem cells are an underlying cause of tumor recurrence and metastasis. verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. for more information, please visit www.versatem.com

Verastem Inc executives and stock owners

Verastem Inc executives and other stock owners filed with the SEC include:

• Brian Stuglik,
  Chief Executive Officer, Director
• Daniel Paterson,
  President, Chief Operating Officer
• Robert Gagnon,
  Chief Financial Officer, Chief Business Officer
• Brian M. Stuglik BPHARM, R.Ph., RPh,
  CEO & Director
• Brian Stuglik R.Ph., RPh,
  CEO & Director
• Daniel W. Paterson,
  COO & Pres
• Robert E. Gagnon,
  Chief Bus. & Financial Officer
• Michael Kauffman,
  Lead Independent Director
• Timothy Barberich,
  Independent Director
• Eric Rowinsky,
  Independent Director
• Alison Lawton,
  Independent Director
• Bruce Wendel,
  Independent Director
• Gina Consylman,
  Independent Director
• John Doyle,
  Investor Relations
• Dr. Michelle Dipp M.D., Ph.D.,
  Co-Founder
• Sean C. Flynn,
  VP, Gen. Counsel & Sec.
• Erin S. Cox,
  Sr. Director of Investor Relations & Corp. Communications
• Dr. Jonathan Pachter Ph.D.,
  Chief Scientific Officer
• Dr. Michelle Dipp,
  Co-Founder
• Dr. Piyush B. Gupta Ph.D.,
  Co-Founder
• Dr. Robert A. Weinberg,
  nder & Former Chair of Scientific Advisory Board
• Richard H. Aldrich M.B.A., Mba,
  Founder and Consultant
• S. Louise Phanstiel,
  Director
• Joseph Chiapponi,
  Vice President of Finance
• John B Green,
  Chief Financial Officer
• Monica Singh,
  General Counsel
• Henri A Termeer,
  Director
• Stephen A Sherwin,
  Director
• Christoph H Westphal,
  Executive Chairman
• Paul A Friedman,
  Director
• Karin Anna Tollefson,
  Director
• Steven H. Bloom,
  Chief Strategy Officer
• Julie B Feder,
  Chief Financial Officer
• Robert Forrester,
  President and CEO
• Ngoc Diep T. Md, Ph D Le,
  Chief Medical Officer
• Joseph M Lobacki,
  Executive VP & CCO
• Gregory Berk,
  Chief Medical Officer
• Capital Investments L.P.Rid...,
  
• Capital Management, L.P.Ra ...,
  
• John Johnson,
  Director
• Management Co. Llc Deer,
  Director
• Iii Lp Chp,
  10% owner
• John K Clarke,
  Director
• Joanna Horobin,
  Chief Medical Officer
• Jonathan Pachter,
  VP, Head of Research
• Fund, L.P. Longwood,
  10% owner
• Venture Partners Vii L.P.Be...,
  
• Stephen Kraus,
  Director
• Ansbert Gadicke,
  Director
• Bioventures V Llcmpm Bioven...,
  
• Piyush Gupta,
  10% owner
• Iii Lpchp Iii Management, L...,
  
• Daniel Calkins,
  Chief Financial Officer
• Frank Neumann,
  Chief Medical Officer
• Paul A. Bunn,
  Director
• Lesley Kim Solomon,
  Director
• Michelle Robertson,
  Director
• Anil Kapur,
  Director
• Dan Paterson,
  President and CEO